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Background: Guidelines have recommended that physicians screen for coronary artery disease (CAD) at the
initiation of dialysis. The purpose of this study was to examine the effects of CAD screening at the initiation of
dialysis on prognosis after starting dialysis
Methods: This retrospective cohort study involved 224 consecutive incident dialysis patients without advanced
cardiac disease. Pharmacological stress myocardial perfusion imaging (MPI) was performed to routinely screen
incident dialysis patients within 3 months of starting dialysis therapy. The influence of MPI on prognosis after
starting dialysis was explored by the propensity score adjustment method. The study outcome was defined as
all-cause mortality and cardiac death.
Results: Of the 224 patients, 164 (73.2 %) underwent MPI screening at initiation of dialysis. During the median
follow-up period of 5.5 years, 77 patients died, among whom 17 (22.1 %) cardiac deaths were observed. The
patients who received MPI had a significantly higher survival rate for all-cause mortality and cardiac death
compared with the patients without MPI (log-rank test, p < 0.001, p = 0.021, respectively). In multiple Cox regression
analysis, MPI screening continued to have a statistically significant negative association with all-cause mortality after
adjusting for confounding variables (hazard ratio 0.581, p = 0.034) and propensity score (hazard ratio 0.568,
p = 0.025).
Conclusions: MPI CAD screening at dialysis initiation could improve prognosis after starting dialysis.
Keywords: Myocardial perfusion imaging, Propensity score, Initiation of dialysis, All-cause mortality, Cardiac deathBackground
Although the underlying mechanism of the cardio-renal
axis in patients with chronic kidney disease (CKD) has
been determined in considerable detail over the past
decade [1], cardiovascular disease is still a leading cause
of death in maintenance dialysis patients worldwide [2,
3] and also in Japan [4]. The accelerated progression of
atherosclerosis during the conservative phase of CKD,
before starting dialysis therapy [5], is thought to be one
of the causes of the high incidence of cardiovascular
events in the dialysis phase [6, 7]. Therefore, it is well* Correspondence: jokinobuhiko@gmail.com
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vascular diseases is observed at the initiation of dialysis.
For example, approximately 50 % of incident asymptom-
atic dialysis patients have been observed to suffer from
advanced coronary artery disease (CAD) [8, 9] and show
poor prognosis after starting dialysis [6, 10]. Based on
this background, guidelines created by several organiza-
tions [11–13] have recommended that physicians screen
for CAD at the initiation of dialysis in order to find it
earlier and improve prognosis. However, it has not yet
been established whether screening for CAD plays a cru-
cial role in improving the prognosis for dialysis patients.
Pharmacological stress myocardial perfusion imaging
(MPI), even in end-stage kidney disease (ESKD) patients,
is one of the most frequently performed procedures for
identifying patients with myocardial ischemia and CAD,is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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nosis [14]. Recently, the severity of abnormal MPI results
has begun to have a great impact on the prediction of car-
diac events in the conservative phase of advanced CKD
patients without cardiovascular disease [15]. Therefore,
MPI is becoming a useful screening procedure for patients
at any stage of kidney disease as a non-invasive procedure
that is not harmful to kidney function.
Our hypothesis for the present study was that screening
for CAD at the initiation of dialysis by using MPI may lead
to improved prognosis after starting dialysis. Therefore,
this study examined the effect of MPI screening for CAD
on the prognosis of incident dialysis patients.
Methods
Study design and patients
This was a retrospective cohort study that involved 314
consecutive patients who started maintenance dialysis for
ESKD at the Toho University Ohashi Medical Center be-
tween January 2001 and December 2010. In order to pre-
cisely evaluate the effect of MPI screening on prognosis,
ESKD patients who already had cardiac disease beforeIncident dialysis patien
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Fig. 1 Schema of the study design. NYHA New York Heart Association, MPI
coronary artery disease, CRT coronary revascularization therapystarting dialysis were excluded. As shown in Fig. 1, 74 pa-
tients met the exclusion criteria as follows: (1) history of
New York Heart Association (NYHA) level III or IV heart
failure, (2) coronary heart disease such as myocardial in-
farction and/or coronary revascularization, or (3) left ven-
tricular dysfunction defined as ejection fraction (EF)
<50 % evaluated by echocardiography. Additionally, 16 pa-
tients who expired within 3 months of starting dialysis
were excluded. The remaining 224 patients were enrolled
into this study, among whom 164 underwent MPI as
screening for CAD. The influence of MPI on prognosis
after starting dialysis was explored by crude cohort ana-
lysis and by the propensity score adjustment method.
All patients provided informed consent to participate
in the study, and the Ethics Committee for Clinical Re-
search at Toho University Ohashi Medical Center ap-
proved the study protocol [Permission no. 13-52, 13-61].
This study adhered to the Declaration of Helsinki.
Data collection
Clinical information from all patients was recorded be-
fore the first hemodialysis (HD) session. All patientsts  
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primary renal disease, previous hospitalization, and his-
tory of hypertension and cardiac disease. We also col-
lected information about the medications the patients
were receiving after starting dialysis. Blood pressure was
recorded from the supine position, and blood samples
were withdrawn immediately before the first HD session.
Serum calcium (Ca) concentrations were corrected by
albumin levels as follows: corrected Ca (cCa) = measured
Ca (mg/dL) + (4—measured albumin level (g/dL)). The
estimated glomerular filtration rate (eGFR) was calcu-
lated using the Japanese equation as follows [16]: eGFR
(mL/min/1.73 m2) = 194 × Cr − 1.094 × Age − 0.287 (for
women × 0.739). Body mass index (BMI) at optimal
weight was calculated as weight (kg) divided by height
(m) squared. All participants were assessed by echocar-
diography at optimum weight after a dialysis session or
on an intermittent day of hemodialysis before discharge.
Ejection fraction was measured as a marker of left ven-
tricular (LV) dysfunction.
MPI as a screening method for coronary artery disease
From January 2001, ESKD patients at our hospital have
been routinely screened for CAD within 3 months of
starting HD therapy, regardless of any suspicion for is-
chemic heart disease (IHD). Pharmacological stress MPI
by using thallium-201 was performed for screening in
164 of the 224 ESKD study patients. Clinically significant
CAD was defined when myocardial perfusion defects
were reversible in patients examined by pharmacological
stress thallium-201 MPI.
Follow-up
The outcome of this study was defined as all-cause mor-
tality and cardiac death. Cardiac death was defined as
death from heart failure, myocardial infarction, or sud-
den death. Information about death was obtained from a
questionnaire survey sent to the maintenance
hemodialysis facilities or the hospital medical records.
The cohort was followed until the end of 2012.
Statistical analysis
Data are summarized as number, prevalence, arithmetic
mean ± standard deviation, or median (interquartile
range), as appropriate. Comparisons of prevalence and
values between groups were performed by Student’s t
test and the χ2 test. In the prospective analysis, the
Kaplan-Meier method was used with the log-rank test.
Prognostic variables were examined by Cox proportional
hazard models, and hazard ratios and 95 % confidence
intervals are reported. p values <0.05 were considered
significant. To adjust for differences in baseline charac-
teristics between the two patient groups (with and with-
out screening MPI), a propensity score analysis wasperformed using multivariate logistic regression model-
ing, including all baseline covariates such as age, sex,
diabetes, BMI, systolic blood pressure (SBP), LV EF, al-
bumin, hemoglobin (Hb), total cholesterol (TC), trigly-
ceride (TG), high-density lipoprotein cholesterol (HDL-
C), eGFR, cCa, phosphate (P), intact-parathyroid hor-
mone (iPTH), c-reactive protein (CRP), and usage of
three medications: renin angiotensin aldosterone system
inhibitor (RAS-I), beta blocker (BB), and statin. The
score was then incorporated into a Cox proportional
hazards model as a covariate. All statistical analyses were




Of the 224 study patients, 164 (73.2 %) patients under-
went MPI screening at the initiation of dialysis (Table 1).
Significantly higher incidence of diabetes, higher dia-
stolic pressure, and higher creatinine concentration
(lower eGFR) were observed in the MPI screening group
compared with the non-MPI group. Although the MPI
group had a younger age, more males, higher SBP, lower
Hb, higher HDL-C, lower cCa, and higher P than the
non-MPI group, no statistically significant differences
were found. Among the 164 patients who underwent the
screening, 27 patients (16.5 %) showed abnormal MPI.
The usage of three medications (statin, RAS-I, and BB)
did not differ significantly between the two groups.
Follow-up
The median follow-up period was 5.5 years. During the
follow-up period, 77 patients died, including 17 cardiac
deaths (22.1 %), as shown in Table 2. A total of 31 pa-
tients were lost to follow-up, and two patients received
renal transplantation and were censored at the time of
the last observation, which was the operation day for
renal transplantation (Fig. 1). At the end of the follow-
up period on December 31, 2012, a total of 114 patients
were alive on maintenance hemodialysis and had com-
pleted follow-up.
As shown in Fig. 2a, the Kaplan-Meier curves indi-
cated that the patients with MPI screening had a signifi-
cantly higher survival rate than the patients who did not
undergo MPI screening (log-rank test, p < 0.001). The
cumulative survival rates at 5 years after starting dialysis
with and without MPI were 74.9 and 49.1 %, respect-
ively. Regarding cardiac death in Fig. 2b, the cardiac
death event-free 5-year survival rate was 94.8 % in pa-
tients with the screening and 86.6 % in patients without
the screening (log-rank test, p = 0.021). After adjusting
by propensity score, the Kaplan-Meier curves still
showed higher survival in patients with MPI than in
those without MPI (dotted line in Fig. 2a, b).
Table 1 Baseline characteristics of incident dialysis patients with
and without MPI screening
MPI screening
Yes No p
n = 164 n = 60
Age (years) 64 ± 12 66 ± 17 0.350
Male (%) 67 55 0.097
BMI (kg/m2) 22 ± 3 22 ± 3 0.170
Diabetes (%) 55 37 0.016
SBP (mmHg) 154 ± 23 147 ± 30 0.069
DBP (mmHg) 78 ± 16 72 ± 11 0.014
Ejection fraction (%) 67 ± 9 66 ± 9 0.403
Albumin (g/dL) 3.3 ± 0.5 3.3 ± 0.5 0.525
Hemoglobin (g/dL) 8.1 ± 1.5 8.4 ± 1.6 0.260
Total cholesterol (mg/dL) 175 ± 53 177 ± 55 0.828
Triglyceride (mg/dL) 123 ± 72 132 ± 61 0.378
HDL-C (mg/dL) 50 ± 17 46 ± 15 0.172
Creatinin (mg/dL) 9.8 ± 3.5 8.6 ± 3.9 0.037
eGFR (mL/min/1.73 m2) 5.0 ± 1.7 5.8 ± 2.3 0.007
cCa (mg/dL) 8.0 ± 1.0 8.2 ± 0.9 0.107
P (mg/dL) 6.2 ± 1.7 5.8 ± 1.6 0.082
iPTH (pg/mL) 338 ± 315 302 ± 170 0.396
CRP (mg/dL) (IQR) 0.1 0.15 0.154
Statin (%) 18 19 0.953
RAS inhibitor (%) 66 53 0.071
Beta blocker (%) 23 17 0.321
Coronary artery disease (%) 27 (16.5)
CRT (%) 9 (5.5)
BMI body mass index, CRP c-reactive protein, CRT coronary revascularization
therapy, SBP systolic blood pressure, DBP diastolic blood pressure, eGFR esti-
mated glomerular filtration rate, HDL-C high-density lipoprotein cholesterol,
RAS renin angiotensin system
Table 2 Causes of death in the present study
Total MPI screening
Yes No
n = 164 n = 60
All cause of death 77
Cardiac disease 17 9 8
Infectious disease 22 12 10
Malignant disease 14 8 6
Cerebrovascular disease 7 6 1
Other 14 10 4
Unknown 3 1 2
Cardiac cause death 17
Heart failure 5 1 4
Myocardial infarction 4 3 1
Sudden death 8 5 3
MPI myocardial perfusion imaging
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groups: 27 patients with CAD, 137 patients without
CAD, and 60 patients without screening. Interestingly,
the 5-year survival rate was the same for patients with
and without CAD (74.9 vs. 74.9 %). After 5 years, the
survival curve of patients with CAD steeply decreased
and became close to the same level as the patients with-
out the screening at 10 years (26.7 vs. 27.4 %) (Fig. 3a).
Similar findings were confirmed in the survival curves
for cardiac death (Fig. 3b).
Coronary angiography and revascularization
Coronary angiography was performed within 180 days in
9 (33.3 %) of 27 with abnormal MPI findings. Seven of
nine with coronary angiography had significant CAD
that was treated with coronary revascularization therapy
(CRT) (one coronary artery bypass surgery and six per-
cutaneous transluminal coronary angioplasty).Cox proportional hazards model for the factors
associated with death
In the univariate Cox proportional hazards model, age,
SBP, serum albumin, Hb, creatinine, eGFR, cCa, CRP,
usage of RAS-I, and MPI screening showed significant
positive or negative associations with death (Table 3).
CRT did not show any significant association with death
(Table 3). In the multiple Cox regression analysis, MPI
screening was significantly associated with all-cause
mortality after adjusting for age, SBP, albumin,
hemoglobin, eGFR, calcium, CRP, and usage of RAS-I
(Table 4). Furthermore, a significant association with all-
cause mortality was observed for MPI screening after
adjusting the propensity score (Table 4).
Age, triglyceride, creatinine, eGFR, corrected Ca, CRP,
and MPI screening showed significant positive or nega-
tive associations with cardiac death in the univariate
Cox proportional hazards model. CRT did not show any
significant association with cardiac death. In multiple
Cox regression analysis, MPI screening was negatively
associated with cardiac death after adjusting for age,
eGFR and, CRP (Table 4). Furthermore, a negative asso-
ciation with cardiac death was observed for MPI screen-
ing after adjusting the propensity score (Table 4).
However, neither of these negative associations was sta-
tistically significant.
Discussion
Main findings of this study
Several studies have observed a high prevalence of CAD
at the initiation of dialysis [8, 9], with severe CAD hav-
ing a large influence on poor prognosis after starting
dialysis [10]. Therefore, international [11, 12] and Japa-
nese [13] guidelines have recommended that physicians





























































































Fig. 2 Comparison of the cumulative survival rate between patients
with and without MPI screening. a Patients with MPI screening
showed a significantly higher survival rate for all-cause mortality
(blue line) compared with patients without the screening (red line) (p
< 0.001, log-rank test). b A significantly higher survival rate for car-
diac death was also observed in patients with MPI screening (blue
line) than in patients without screening (red line) (p = 0.021, log-rank
test). The blue and red dotted lines indicate the propensity score-
adjusted survival curves for each patient group of the same color.
Even after adjusting the propensity score, higher survival rates
remained for all-cause mortality (a) and cardiac death (b)
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However, to date, no evidence has been obtained to
prove the effect of screening on prognosis in dialysis pa-
tients. The present study demonstrated that MPI screen-
ing for CAD at the initiation of dialysis may lead to
improved prognosis in incident dialysis patients without
cardiac disease. An approximately 50 % risk reduction
for death produced by the screening was confirmed by
using crude cohort analysis, and also by using propensity
score adjustment analysis. Our findings may serve as evi-
dence to support the international guidelines [11, 12].
Effect of CAD screening on mortality
Several previous studies have shown the effect of screen-
ing on prognosis in the field of cardiovascular disease.
Thompson et al. reported the elegant results of their
randomized controlled study, in which ultrasound
screening for abdominal aortic aneurysm (AAA) resulted
in a reduction in all-cause mortality and was beneficial
for AAA-related mortality in a population-based sample
of men aged 65–74 years [17]. A relative 42 % risk re-
duction for AAA-related death and 3 % risk reduction in
all-cause mortality were confirmed in the screening
group compared with the non-screening group. Simi-
larly, Lindholt et al. conducted a randomized single-
center mass screening trial for AAA [18]. Screening re-
duced the number of emergency operations by 68 % and
lowered the mortality of AAA by 73 % over a 10-year
period in the screening group compared with the control
group. Although these reports demonstrate the benefit
of screening for AAA in the asymptomatic general
population, which is different from the aim of the
present study, it is not surprising that the same benefi-
cial findings are confirmed by screening for CAD even
in ESKD patients without cardiac disease.
Conversely, several reports have demonstrated that
screening for disease had no beneficial effects on mortal-
ity. In a randomized controlled trial [19], ultrasound
screening for AAA was found to be not effective in men
aged 65–83 years and did not reduce overall death rates.
Another study [20] showed that echocardiographic
screening for structural and valvular heart disease in the
general population provided no benefit for mortality or
for the risk of myocardial infarction or stroke. The rea-
sons for the contrary outcomes between those studies
remain unclear; however, some potential underlying rea-
sons might exist. The prevalence of an implicit target
disease for screening in a study cohort would be an im-
portant factor affecting the outcome for screening suc-
cess. If the prevalence of a target cardiovascular disease
is very low in a study cohort, there is a high possibility
that the screening will not show any beneficial effect if
the study cohort is not enough large. Indeed the clinical
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CAD (-) vs. CAD (+): p=0.322
CAD (-) vs. MPI No:  p=0.009
CAD (+) vs. MPI No: p=0.512
a
b
Fig. 3 Comparison of the cumulative survival rate between three
patient groups: with CAD, without CAD, and without MPI screening.
a Patients without CAD by MPI screening showed a significantly
higher survival rate for all-cause mortality (blue line) compared with
patients without screening (red line) (p < 0.001, log-rank test). The
survival curve for the patients with CAD (dotted blue line) depicts
almost the same pattern as the patients without CAD (blue line) until
the sixth year of the follow-up period; then, the curve steeply drops
to the level of the patients without screening (red line) at 10 years.
b A significantly higher survival rate for cardiac death was also
observed in patients without CAD by MPI screening (blue line) than
in patients without screening (red line) (p = 0.009, log-rank test).
Similar to the curves for all-cause mortality, the survival curve for the
patients with CAD (dotted blue line) shows almost the same pattern
as the patients without CAD (blue line) until the sixth year of the
follow-up period; then, the curve steeply drops to below the level of
the patients without screening (red line) at 10 years
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tomatic, low-risk adults with resting or stress electrocar-
diography, stress echocardiography, or stress myocardial
perfusion imaging [21]. The accuracy of a screening test
would also play an important role in the study outcome.
A lack of sufficient sensitivity and specificity to capture
a target disease would crucially influence the results. It
is well known that a high prevalence (40–50 %) of
underlying CAD is observed in asymptomatic ESKD pa-
tients [8, 9, 22]. Even in ESKD patients, the accuracy of
the pharmacological stress MPI for detecting CAD is re-
ported to be sufficiently high, with a sensitivity of 80 %
and specificity of 73 % observed in 42 chronic dialysis
patients [23] and a sensitivity of 86 % and specificity of
79 % in 80 type I diabetes ESKD patients [24]. Also, the
event rate after screening influences the study outcome.
Young et al. assessed whether routine screening for
CAD by MPI affects cardiac outcomes in asymptomatic
type 2 diabetic patients [25]. These investigators con-
cluded that cardiac event rates were not significantly re-
duced by MPI screening over a follow-up period of
4.8 years due at least in part to a low cardiac event rate
of 2.9 %. In the present study, during the median follow-
up period of 5.5 years, the cardiac death rate was 22.1 %,
which is seven times higher than that in the Young
study. This is also one of the reasons for the beneficial
effect of screening. Therefore, although we used a small
sample of ESKD patients in a single-center study, we be-
lieve that the findings of the present study provide valu-
able data.
Greater beneficial effect for all-cause mortality than for
cardiac death
In general, a greater beneficial effect is expected for car-
diac death than for all-cause mortality by MPI screening.
In the present study, MPI screening had a negative impact
on cardiac death; however, this did not reach a statistically
significant level in multivariate Cox proportional hazards
Table 3 Cox proportional hazards model for identifying the factors associated with all-cause mortality and cardiac death
All cause of death Cardiac cause death
HR 95 % CI p value HR 95 % CI p value
Age (per year) 1.053 1.032–1.074 <0.001 1.056 1.012–1.102 0.012
Male 1.568 0.956–2.573 0.075 0.912 0.347–2.400 0.852
BMI (kg/m2) 0.940 0.873–1.014 0.108 1.010 0.870–1.174 0.893
Diabetes (yes) 1.119 0.715–1.751 0.624 0.889 0.343–2.309 0.810
SBP (mmHg) 0.991 0.982–1.000 0.040 0.995 0.977–1.013 0.559
DBP (mmHg) 0.987 0.970–1.004 0.121 0.988 0.954–1.024 0.517
Ejection fraction (%) 0.989 0.965–1.013 0.355 0.957 0.914–1.002 0.063
Albumin (g/dL) 0.503 0.307–0.823 0.006 0.613 0.209–1.792 0.371
Hemoglobin (g/dL) 1.171 1.006–1.363 0.042 1.305 0.946–1.802 0.105
Total cholesterol (mg/dL) 1.001 0.997–1.006 0.613 1.006 0.998–1.014 0.156
Triglyceride (mg/dL) 1.001 0.997–1.004 0.701 1.004 1.000–1.009 0.046
HDL-C (mg/dL) 0.995 0.980–1.010 0.508 0.979 0.944–1.017 0.275
Creatinin (mg/dL) 0.818 0.745–0.899 <0.001 0.725 0.577–0.913 0.006
eGFR (mL/min/1.73 m2) 1.292 1.166–1.431 <0.001 1.332 1.074–1.650 0.009
cCa (mg/dL) 1.303 1.027–1.654 0.030 1.932 1.112–3.359 0.020
P (mg/dL) 0.867 0.744–1.010 0.067 0.783 0.560–1.094 0.152
iPTH (pg/mL) 0.999 0.998–1.000 0.155 0.999 0.996–1.001 0.389
CRP (mg/dL) 1.29 1.055–1.578 0.013 1.497 1.049–2.138 0.026
Statin (%) 1.273 0.710–2.282 0.418 1.272 0.363–4.466 0.707
RAS inhibitor (%) 0.522 0.333–0.820 0.005 0.502 0.193–1.307 0.158
Beta blocker (%) 1.083 0.630–1.861 0.773 1.559 0.546–4.448 0.407
MPI screening 0.449 0.284–0.708 0.001 0.342 0.131–0.887 0.027
Coronary artery disease 1.376 0.698–2.716 0.357 1.999 0.494–8.091 0.332
CRT 1.102 0.274–4.439 0.891 2.673 0.167–42.794 0.487
BMI body mass index, CRP c-reactive protein, CRT coronary revascularization therapy, SBP systolic blood pressure, DBP diastolic blood pressure, eGFR estimated
glomerular filtration rate, HDL-C high-density lipoprotein cholesterol, RAS renin angiotensin system
Tanaka et al. Renal Replacement Therapy  (2016) 2:22 Page 7 of 9analysis. Few cardiac death events during the follow-up
period may lead to insufficient statistical power for ana-
lysis. However, a possible explanation can be raised for
this issue. The first possible explanation is that the pa-
tients with MPI screening may be a special sub-cohort
who pays more attention to their own health, compared
to the patients without the screening. Although it is a mat-
ter of speculation, screening for CAD at the initiation of
dialysis could be a trigger to alert patients to be vigilant
regarding their overall health. This would be a reason why
the screening might exert a more beneficial effect onTable 4 Freedom from events of MPI
Crude
HR 95 % CI
All cause of death 0.581a 0.352–0.959a
Cardiac death 0.419b 0.157–1.118b
CRP c-reactive protein, SBP systolic blood pressure, eGFR estimated glomerular filtra
aAdjusted by age, SBP, albumin, hemoglobin, eGFR, calcium, CRP, and RAS inhibitor
bAdjusted by age, eGFR, and CRP, MPI myocardial perfusion imagingimproving prognosis for all-cause mortality than for car-
diac death.
The second possible explanation may relate to the re-
sults of our previous study [26]. In that study, we ana-
lyzed the survival rates for major adverse cardiac events
in incident dialysis patients without CAD and found that
even in patients without significant CAD, cardiac events
occurred after 1 year of starting dialysis. We have pro-
posed to administer a second screening for CAD at least
2 years after starting dialysis, even if no significant CAD
was confirmed at the initiation of dialysis. It isPropensity score adjusted
p value HR 95 % CI p value
0.034a 0.568 0.347–0.932 0.025
0.082b 0.491 0.175–1.377 0.177
tion rate, RAS renin angiotensin system
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be made by patients who underwent a first screening
compared with the patients without screening; conse-
quently, the mortality rate may decrease in the patients
who undergo screening for CAD.
The third possible explanation is attempts to lower the
rate of cardiac death. Twenty-seven patients among the
164 (16.4 %) who received screening suffered from CAD
in the present study. Physicians may pay more attention
and add intensive treatment to those patients to improve
prognosis. In fact, it was found that the 5-year survival
rate of the 27 ESKD patients with CAD was 74.9 %,
which is not inferior to the 5-year survival rate of 74.9 %
in the 137 ESKD patients without CAD. The 1-year sur-
vival rate showed a large difference (26.7 vs. 64.5 %) be-
tween patients with and without CAD. On the other
hand, in the 60 ESKD patients without the screening,
approximately 10 patients (about 16.5 %) were calculated
to have suffered from CAD if the same prevalence in the
164 ESKD patients with the screening had occurred.
Failure to pay attention and insufficient management in
those 10 patients may have played a role, at least in part,
in poor prognosis for all-cause mortality. However, the
possible advantages of screening on prognosis could not
be fully explained based only on the difference in man-
agement of CAD.
The fourth possible explanation of greater benefit for
all-cause mortality than for cardiac death is the potential
for selection bias. The design of our study was an obser-
vational cohort study, not a randomized prospective
study. It cannot be denied that relatively low-risk pa-
tients were selected and underwent the screening by
chance. In order to minimize the selection bias, accord-
ing to the analytical technique used in the present study,
we calculated the propensity score by using all back-
ground factors to adjust for differences in baseline char-
acteristics. As shown in Table 4, an approximately 50 %
risk reduction for death engendered by the screening ap-
peared even after adjusting the propensity score. There-
fore, it is more plausible that screening at the initiation
of dialysis could lead to a better prognosis for incident
dialysis than ever before.The timing of screening in CKD patients
To improve the prognosis of hemodialysis patients, the
best goal we should reach is to start dialysis without any
cardiovascular complication. Therefore, we think that
the screening should be performed in earlier predialytic
phase of CKD such as CKD 3 or 4. The initiation of HD
as timing for screening may be too late. This would be a
reason why the beneficial effect of MPI screening at the
initiation of dialysis on cardiac mortality in this study
showed marginal.Limitations
The present study had some limitations. In order to ac-
curately evaluate the effects of screening on prognosis, a
prospective randomized controlled study is the gold
standard. However, based on the recommendations of
international guidelines [11, 12], it is impossible to plan
a study in which the patients are randomly divided ac-
cording to whether screening is performing. We felt
constrained to use the propensity score adjustment
method to prove our hypothesis. Another limitation was
that this was a single-center observational study with a
relatively small number of patients. A larger-scale study
should be conducted in the future.
Conclusions
Screening for CAD at the initiation of dialysis could lead
to better prognosis after starting dialysis. This finding is
considered to be in line with the recommendation of
international guidelines [11, 12]. A larger-scale random-
ized controlled study is needed to confirm this finding.
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